| 摘要 |
Disclosed is a method of predicting the response to a treatment with a HER dimerization inhibitor in a patient comprising the steps of: a) assessing in a biological sample from the patient, wherein the biological sample is blood serum, the level of expression of: - a marker protein encoded by the transforming growth factor alpha marker gene; or - a combination of marker proteins encoded by marker genes wherein the combination of marker proteins encoded by marker genes consists of the marker proteins encoded by: - the transforming growth factor alpha and the HER2 marker gene; - the transforming growth factor alpha and the epidermal growth factor marker gene; - the amphiregulin and the transforming growth factor alpha marker gene; - the transforming growth factor alpha, the epidermal growth factor and the HER2 marker gene; - the amphiregulin, the epidermal growth factor and the transforming growth factor alpha marker gene; - the amphiregulin, the transforming growth factor alpha and the HER2 marker gene; or - the amphiregulin, the epidermal growth factor, the transforming growth factor alpha and the HER2 marker gene, b) predicting the response to the treatment with the HER dimerization inhibitor in the patient by evaluating the results of step a), wherein the step a) of assessing the marker protein encoded by the marker gene or the combination of marker proteins encoded by the marker genes comprises a1) assessing the level of expression of the marker protein encoded by the marker gene or the combination of marker proteins encoded by the marker genes, a2) determining whether the level of expression assessed in step al) is above or below a threshold value, wherein a level of expression of either above or below the threshold value is predictive of either a positive or a negative response to treatment with the HER dimerization inhibitor.
|
